Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sultan Qaboos Univ Med J ; 24(1): 44-51, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38434464

RESUMO

Objectives: Dimethyl fumarate (DMF) is known to cause lymphopenia when used to treat patients with multiple sclerosis (MS). However, research on DMF therapy in the Arab world, especially in Oman, is scarce. This study aimed to analyse the prevalence of lymphopenia among Omani patients with MS and their reasons for discontinuing DMF therapy. Methods: In this retrospective study, the medical records of Omani patients with MS who were treated using DMF at two tertiary hospitals in Muscat, Oman, from February 2017 to February 2023 were reviewed. Their demographic, clinical and laboratory data were retrieved and analysed. Absolute lymphocyte count values at baseline and at the last follow-up, as well as the reasons for discontinuing DMF therapy, were collected. Descriptive and inferential statistical techniques were used for data analysis. Binary-logistic regression analysis was used to identify the risk factors for DMF-induced lymphopenia. Results: A total of 64 Omani patients with MS were included in this study. The majority of the study participants (n = 40; 63%) were female. All included patients started DMF therapy at the mean age of 33 ± 7.7 years. After administration of DMF, 14 (21.9%) patients developed grades 1-3 of lymphopenia. The DMF therapy was discontinued for 23 (36.0%) patients, mainly in response to adverse events or confirmed pregnancy. Female gender was the only significant predictor of DMF-induced lymphopenia (P = 0.037). Conclusions: Most Omani patients with MS had mild lymphopenia (grades 1-2). Early adverse events and pregnancy were the main reasons provided for discontinuing DMF therapy.


Assuntos
Linfopenia , Esclerose Múltipla , Gravidez , Humanos , Feminino , Masculino , Adulto , Fumarato de Dimetilo/efeitos adversos , Esclerose Múltipla/tratamento farmacológico , Estudos Retrospectivos , Linfopenia/induzido quimicamente , Linfopenia/epidemiologia , Mundo Árabe
2.
Mult Scler Relat Disord ; 48: 102729, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33418310

RESUMO

A 31-year-old pregnant woman presented with headache, fever and left-sided focal motor seizures, which progressed to bilateral tonic-clonic seizures. Her medical history included Crohn's disease treated with azathioprine and adalimumab, which were discontinued when she became pregnant. Her cerebro-spinal fluid was entirely normal and viral PCR negative. Extensive testing for infectious, autoimmune or malignant causes of encephalitis were non-revealing. MRI head showed unilateral cortical FLAIR-hyperintensity which on interval scans was seen bilaterally. Anti-myelin-oligodendrocyte glycoprotein (MOG)-IgG was positive leading to a diagnosis of cortical FLAIR-hyperintense lesions in Anti-MOG-associated Encephalitis with seizures (FLAMES).


Assuntos
Doença de Crohn , Encefalite , Adulto , Autoanticorpos , Doença de Crohn/complicações , Doença de Crohn/diagnóstico por imagem , Doença de Crohn/tratamento farmacológico , Encefalite/complicações , Encefalite/diagnóstico por imagem , Feminino , Humanos , Terapia de Imunossupressão , Imageamento por Ressonância Magnética , Glicoproteína Mielina-Oligodendrócito , Convulsões/diagnóstico por imagem , Convulsões/tratamento farmacológico , Convulsões/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...